“Spesolimab Improves Quality of Life in Generalized Pustular Psoriasis (GPP) As Measured by Proportion of Patients With Dermatology Life Quality Index (DLQI) Scores of 0 or 1 and Reduction in Pain Severity Over Time: Results From the EFFISAYIL® 2 Trial”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s652. https://doi.org/10.25251/fmm5fj59.